

University of Groningen

Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated

Harinck, Femme; Kluijt, Irma; van Mil, Saskia E.; Waisfisz, Quinten; van Os, Theo A. M.; Aalfs, Cora M.; Wagner, Anja; Olderode-Berends, Maran; Sijmons, Rolf H.; Kuipers, Ernst J.

Published in:
European Journal of Human Genetics

DOI:
[10.1038/ejhg.2011.226](https://doi.org/10.1038/ejhg.2011.226)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2012

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Harinck, F., Kluijt, I., van Mil, S. E., Waisfisz, Q., van Os, T. A. M., Aalfs, C. M., Wagner, A., Olderode-Berends, M., Sijmons, R. H., Kuipers, E. J., Poley, J-W., Fockens, P., & Bruno, M. J. (2012). Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. *European Journal of Human Genetics*, 20(5), 577-579. <https://doi.org/10.1038/ejhg.2011.226>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

SHORT REPORT

Routine testing for *PALB2* mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated

Femme Harinck^{*1}, Irma Kluijdt², Saskia E van Mil³, Quinten Waisfisz³, Theo AM van Os⁴, Cora M Aalfs⁴, Anja Wagner⁵, Maran Olderoode-Berends⁶, Rolf H Sijmons⁶, Ernst J Kuipers^{1,7}, Jan-Werner Poley¹, Paul Fockens⁸ and Marco J Bruno¹

PALB2-mutation carriers not only have an increased risk for breast cancer (BC) but also for pancreatic cancer (PC). Thus far, *PALB2* mutations have been mainly found in PC patients from families affected by both PC and BC. As it is well known that the prevalence of gene mutations varies between different populations, we studied the prevalence of *PALB2* mutations in a Dutch cohort of non-*BRCA1/2* familial PC (FPC) families and in non-*BRCA1/2* familial BC (FBC) families with at least one PC case. Mutation analysis included direct sequencing and multiplex ligation-dependent probe amplification (MLPA) and was performed in a total of 64 patients from 56 distinct families (28 FPC families, 28 FBC families). In total, 31 patients (48%) originated from FPC families; 24 were FPC patients (77%), 6 had a personal history of BC (19%) and 1 was a suspected carrier (3.2%). The remaining 33 patients (52%) were all female BC patients of whom 31 (94%) had a family history of PC and 2 (6.1%) had a personal history of PC. In none of these 64 patients a *PALB2* mutation was found. Therefore, *PALB2* does not have a major causal role in familial clustering of PC and BC in non-*BRCA1/2* families in the Dutch population.

European Journal of Human Genetics (2012) 20, 577–579; doi:10.1038/ejhg.2011.226; published online 14 December 2011

Keywords: familial pancreatic cancer; pancreatic cancer susceptibility; breast cancer susceptibility; mutation analysis; hereditary cancer

INTRODUCTION

Recently, it has become clear that the Fanconi gene *FANCN/PALB2* (partner and localizer of *BRCA2*) should not only be considered as a susceptibility gene for breast cancer (BC)¹ but also as a susceptibility gene for pancreatic cancer (PC).² Mutations in this gene may be associated with familial clustering of PC and BC.^{1–10}

Previous studies have shown that *PALB2*-mutation-positive familial BC (FBC) patients were significantly more likely to have a relative with PC,⁵ and that nearly all *PALB2*-mutation positive familial PC (FPC) families were affected by at least one BC case.⁴

Given these findings and the fact that the prevalence of gene mutations varies between different populations, we aimed to determine the prevalence of *PALB2* mutations in Dutch cohorts of non-*BRCA1/2* FPC patients and of non-*BRCA1/2* FBC patients with a personal or family history of PC.

MATERIALS AND METHODS

The prevalence of germline mutations in *PALB2* was investigated in Dutch non-*BRCA1/2* FPC patients and non-*BRCA1/2* FBC patients with a personal or family history of PC.

FPC families were defined as families with PC in either ≥ 2 first-degree relatives (FDRs), ≥ 3 relatives (FDR and second-degree relative (SDR)) or 2

SDRs of whom one was < 50 years at diagnosis and did not meet diagnostic criteria of specific other cancer syndromes.¹¹ These families were identified in the registries of the Clinical Genetic Centres of Amsterdam (Academic Medical Centre-University Medical Centre Amsterdam and Netherlands Cancer Institute), Rotterdam (Erasmus MC-University Medical Centre Rotterdam), and Groningen (University Medical Centre Groningen), consisting of a total of 40 FPC families. In 28 of these families, DNA was available for *PALB2* mutation analysis. In families in which DNA was available of multiple family members affected by PC, *PALB2* mutation analysis was performed in DNA of all cases. In families without available DNA from PC patients, mutation analysis was performed in family members affected by BC. In one family, mutation analysis was performed in a suspected carrier; this suspicion was based on the position of this individual in the pedigree; this specific case had a sibling with PC and a child with PC.

The FBC patients were taken from the registry from the Netherlands Cancer Institute and consisted of non-*BRCA1/2* BC patients that fulfilled the Dutch clinical criteria for *BRCA1* and *BRCA2* mutation testing, which include (1) BC diagnosis at age < 35 years, (2) bilateral BC of which one diagnosis at age < 50 years, (3) at least two FDR with BC at an age < 50 years, (4) at least three FDR or SDR with BC, and (5) one < 50 years at diagnosis. From this registry, patients with a personal history of both BC and PC, and BC patients with a FDR or SDR with PC were selected. In families in which DNA was available of multiple affected family members, *PALB2* mutation analysis was performed in all cases.

¹Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands; ²Familial Cancer Clinic, The Netherlands Cancer Institute Amsterdam, Amsterdam, The Netherlands; ³Department of Clinical Genetics: Section Oncogenetics, VU University Medical Centre, Amsterdam, The Netherlands;

⁴Department of Clinical Genetics, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; ⁵Department of Clinical Genetics, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands; ⁶Department of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands;

⁷Department of Internal Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands; ⁸Department of Gastroenterology and Hepatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

*Correspondence: Dr F Harinck, Erasmus MC-University Medical Centre Rotterdam, Department of Gastroenterology and Hepatology, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. Tel: +31 (0)10 7032825; Fax: +31 (0)10 7034682; E-mail: f.harinck@erasmusmc.nl

Received 10 August 2011; revised 24 October 2011; accepted 26 October 2011; published online 14 December 2011

At the time of genetic counselling, patients had given written informed consent to use their DNA for the search for new cancer-susceptibility genes.

Table 1 Characteristics of tested families (*n*=56) and cases (*n*=64)

	<i>n</i>	%
<i>FPC families n=28</i>		
Total number of cases tested	31	
Type of case in whom <i>PALB2</i> mutation analysis was performed		
Personal history of FPC	24	77
Personal history of BC	6	19
Suspected carrier	1	3.2
<i>BC-PC family n=28</i>		
Total number of cases tested	33	
Type of case in whom <i>PALB2</i> mutation analysis was performed		
Personal history of BC with FDR or SDR with PC	31	94
Personal history of both BC and PC	2	6.1
Type of Dutch clinical criteria for <i>BRCA1/2</i> mutation testing per family		
BC diagnosis at age <35 years	6	21
Bilateral BC, one diagnosis at age <50 years	2	7.1
≥2 FDR with BC at age <50 years	12	43
≥3 FDR or SDR with BC, one <50 years at diagnosis	8	29

Table 2 Detailed description of FPC families (*n*=28) and PC-affected FBC families

<i>FPC families n=28</i>		
Total number of PC cases (<i>n</i>)	70	
Confirmed by medical or pathology report (<i>n</i> , %)	57	81
Mean age at PC diagnosis (years, SD)	61	11.5
Mean age at PC diagnosis in tested case <i>n</i> =24 (years, SD)	60	11.4
Male gender of PC case (<i>n</i> , %)	38	54
Number of families ≥3 family members diagnosed with PC (<i>n</i> , %)	10	36
Number of families affected by BC (<i>n</i> , %)	14	50
<i>BC-PC families n=28 and cases n=33</i>		
Mean age at BC diagnosis in tested case (years, SD)	42	9.5
Total number of PC cases (<i>n</i>)	29	
Confirmed by medical or pathology report (<i>n</i> , %)	24	83
Mean age at PC diagnosis (years, SD)	70	11.9
Male gender of PC case (<i>n</i> , %)	12	41

Table 3 Overview of literature on role of *PALB2* mutations in FPC and in BC families affected by PC

<i>Role of <i>PALB2</i> mutations in FPC</i>						
Study	Country	Total <i>n</i>	Population (families)		<i>PALB2</i> +families	
			<i>FPC</i> <i>n</i>	<i>FPC with BC</i> <i>n</i>	<i>n</i> (%; 95% CI)	<i>PALB2</i> +families with BC
Jones ²	USA	96	96	n.s.	3 (3.1, n.s.)	2/3 (75%)
Tischkowitz ⁴	Canada	101	80	21	1 (1.0, n.s.)	1/1 (100%)
Slater ¹⁰	Europe	81	67	15	3 (3.7, 0.8–10.4%)	3/3 (100%)
Current study	The Netherlands	28	14	14	0 (0, n.a.)	n.a.
<i>Role of <i>PALB2</i> mutations in BC families affected by PC</i>						
Study	Country	Total <i>n</i>	Population (families)		<i>PALB2</i> +families	
			Pers. Hx BC and F/SDR PC <i>n</i>	Pers. Hx BC and PC <i>n</i>	<i>n</i> (%; 95% CI)	
Adank ¹⁴	The Netherlands	45	45	0	0 (0, n.a.)	
Peterlongo ⁸	Italy	62	62	0	3 (4.8, 0.99–13.29%)	
Stadler ⁹	USA	77	55	22	0 (0, n.a.)	
Hofstatter ⁷	USA	94	91	3	2 (2.1, 0.4–6.5%)	
Current study	The Netherlands	28	26	2	0/28 (0%)	

Abbreviations: n.a., not applicable; n.s., not specified.

Sequencing and multiplex ligation-dependent probe amplification (MLPA)

The presence of germline mutations in *PALB2* was evaluated by direct sequencing of the entire coding region and by sequencing intron–exon boundaries on genomic DNA isolated from whole blood. Primer pairs that were used have been previously described.¹²

The presence of large genomic deletions in *PALB2* was analysed by MLPA using the MLPA P057 kit of MRC-Holland (Amsterdam, The Netherlands) as previously described.¹³ As a positive control, genomic DNA from the previously described *PALB2* FA patient EUFA1341 was included in the analysis.¹²

RESULTS

PALB2 mutation analysis was performed in a total of 64 patients from 56 distinct families (28 FPC families, 28 FBC families; Table 1). In total, 31 patients (48%) originated from FPC families; 24 were FPC patients (77%), 6 had a personal history of BC (19%) and 1 was a suspected carrier (3.2%). The remaining 33 patients (52%) were all female BC patients of whom 31 (94%) had a family history of PC and 2 (6.1%) had a personal history of PC.

The 28 FPC families had a total of 70 affected patients with PC of which 57 (81%) were confirmed by medical (*n*=11) or pathology reports (*n*=46) (Table 2). The mean age at time of PC diagnosis was 61 years (SD ± 11.5). In total, 38 of the PC patients (54%) were male. Ten FPC families (36%) had at least three family members diagnosed with PC. Fourteen FPC families (50%) were affected by BC. Among the 33 tested patients from 28 FBC families, the mean age at BC diagnosis was 42 years (SD ± 9.5). The total number of PC cases was 29, of which 24 (83%) were confirmed by medical (*n*=13) or pathology report (*n*=11). The mean age at PC diagnosis was 70 years (SD ± 10.9) and 41% (*n*=12) of all PC cases were male.

In none of these cases was a *PALB2* mutation found by direct sequencing and MLPA.

DISCUSSION

Our data provide further evidence that there is a limited causal role for *PALB2* mutations in both FPC and FBC, as we did not identify any *PALB2* mutations in our Dutch cohort of 28 FPC families and 28 FBC families affected with at least one case of PC.

Since the recent recognition of *PALB2* as BC- and PC-susceptibility gene,^{1,2} a number of studies have been carried out to investigate the role

of *PALB2* in different patient populations. Our results are in line with the results of these previous reports in which no *PALB2* mutations,^{9,14} or low prevalence of *PALB2* mutations,^{2,4,7–8,10} were found. It should be mentioned that the relatively small sample size could be a possible explanation for that no mutation carrier was identified in the current study. Even if a larger sample size might have detected sporadic cases, its results do show that the role of *PALB2* in this particular setting is insignificant. When combining our data with the previously published data, *PALB2* is involved in only 2.3% (7/306, range 0–3.7%, 95% CI 0.6–40%) of all FPC families and in 1.6% (5/306, range 0–4.8%, 95% CI 0.21–31%) of all FBC families with PC cases (Table 3).

Although *PALB2* is involved in the clustering of both PC and BC, it explains only a small fraction of the clustering, and it is therefore crucial that future research is directed towards identifying the gene(s) that are involved in the development of both FPC and FBC. Knowledge of additional PC- and BC-susceptibility genes will be helpful in the counselling of family members from FPC and FBC families, as this will improve our ability to identify individuals at increased risk of developing PC and BC. Furthermore, it will have implications on the effectiveness of screening which will be highest when only directed towards individuals at risk.

In conclusion, our results provide further evidence for the low prevalence of *PALB2* mutations among non-*BRCA1/2* FPC families and FBC families with PC cases. Therefore, routine analysis of this gene in these families is not warranted. Future research should be directed towards specifying subtypes of FPC/FBC families in which *PALB2* analysis is useful towards identifying other gene(s) involved in the development of PC and BC.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

On behalf of the Dutch Research Group of Pancreatic Cancer Surveillance in High-Risk Individuals (in alphabetical order): Amsterdam Medical Center:

Cora M Aalfs, Marcel GW Dijkgraaf, Paul Fockens, Dirk J Gouma, Jeanin E van Hooft, C Yung Nio, Theo AM van Os, Ellen MA Smets. Erasmus Medical Center: Katharina Biermann, Marco J Bruno, Henny van Duijl, Casper HJ van Eijck, Femme Harinck, Nanda Krak, Jan-Werner Poley, Anja Wagner. The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital: Eveline MA Bleiker, Annemieke Cats, Irma Kluij, Anja van Rens, Grace Sidharta, Senno Verhoef. University Medical Center Groningen: Hendrik M van Dullemen, Rolf H Sijmons.

- 1 Rahman N, Seal S, Thompson D *et al*: *PALB2*, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat Genet* 2007; **39**: 165–167.
- 2 Jones S, Hruban RH, Kamiyama M *et al*: Exomic sequencing identifies *PALB2* as a pancreatic cancer susceptibility gene. *Science* 2009; **324**: 217.
- 3 Erkkö H, Xia B, Nikkila J *et al*: A recurrent mutation in *PALB2* in Finnish cancer families. *Nature* 2007; **446**: 316–319.
- 4 Tischkowitz MD, Sabbaghian N, Hamel N *et al*: Analysis of the gene coding for the BRCA2-interacting protein *PALB2* in familial and sporadic pancreatic cancer. *Gastroenterology* 2009; **137**: 1183–1186.
- 5 Casadei S, Norquist BM, Walsh T *et al*: Contribution of inherited mutations in the BRCA2-interacting protein *PALB2* to familial breast cancer. *Cancer Res* 2011; **71**: 2222–2229.
- 6 Hellebrand H, Sutter C, Honisch E *et al*: Germline mutations in the *PALB2* gene are population specific and occur with low frequencies in familial breast cancer. *Hum Mutat* 2011; **32**: E2176–E2188.
- 7 Hofstatter EW, Domchek SM, Miron A *et al*: *PALB2* mutations in familial breast and pancreatic cancer. *Fam Cancer* 2011; **10**: 225–231.
- 8 Peterlongo P, Catucci I, Pasquini G *et al*: *PALB2* germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. *Breast Cancer Res Treat* 2011; **126**: 825–828.
- 9 Stadler ZK, Salo-Mullen E, Sabbaghian N *et al*: Germline *PALB2* mutation analysis in breast-pancreas cancer families. *J Med Genet* 2011; **48**: 523–525.
- 10 Slater EP, Langer P, Niemczyk E *et al*: *PALB2* mutations in European familial pancreatic cancer families. *Clin Genet* 2010; **78**: 490–494.
- 11 Brand RE, Lerch MM, Rubinstein WS *et al*: Advances in counselling and surveillance of patients at risk for pancreatic cancer. *Gut* 2007; **56**: 1460–1469.
- 12 Xia B, Dorsman JC, Ameziame N *et al*: Fanconi anemia is associated with a defect in the BRCA2 partner *PALB2*. *Nat Genet* 2007; **39**: 159–161.
- 13 Ameziame N, van den Ouweland AM, Adank MA *et al*: Lack of large genomic deletions in *BRIP1*, *PALB2*, and *FANCD2* genes in *BRCA1/2* negative familial breast cancer. *Breast Cancer Res Treat* 2009; **118**: 651–653.
- 14 Adank MA, van Mil SE, Gille JJ, Waisfisz Q, Meijers-Heijboer H: *PALB2* analysis in BRCA2-like families. *Breast Cancer Res Treat* 2011; **127**: 357–362.